Anti-ICOS therapeutic antibody (Pre-made Vopratelimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, vopratelimab targets and binds to ICOS expressed on certain T cells.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-629-1mg	1mg	3090
GMP-Bios-ab-629-10mg	10mg	21890
GMP-Bios-ab-629-100mg	100mg	148000
GMP-Bios-ab-629-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-ICOS therapeutic antibody (Pre-made Vopratelimab biosimilar,Whole mAb)
INN Name	Vopratelimab
Target	ICOS
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Jounce Therapeutics
Conditions Approved	na
Conditions Active	Solid tumours;Urogenital cancer;Non-small cell lung cancer
Conditions Discontinued	na
Development Tech	na